Inventiva (NASDAQ:IVA) Sets New 12-Month Low – Time to Sell?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) hit a new 52-week low on Thursday . The company traded as low as $3.31 and last traded at $3.2460, with a volume of 194757 shares changing hands. The stock had previously closed at $3.45.

Wall Street Analysts Forecast Growth

IVA has been the topic of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research report on Friday, July 17th. Cantor Fitzgerald assumed coverage on shares of Inventiva in a report on Friday, July 17th. They set an “overweight” rating on the stock. Piper Sandler reiterated an “overweight” rating on shares of Inventiva in a research report on Wednesday, September 16th. Finally, Guggenheim upped their price target on shares of Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Inventiva currently has a consensus rating of “Buy” and an average target price of $15.75.

Inventiva Trading Down 7.4%

The stock’s 50-day simple moving average is $4.47 and its 200-day simple moving average is $4.79.

Hedge Funds Weigh In On Inventiva

Several large investors have recently made changes to their positions in IVA. Engineers Gate Manager LP raised its holdings in Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after purchasing an additional 43,280 shares during the period. Seven Fleet Capital Management LP purchased a new stake in Inventiva in the first quarter worth about $1,111,000. Persistent Asset Partners Ltd purchased a new stake in Inventiva in the fourth quarter worth about $603,000. NEXTBio Capital Management LP purchased a new stake in Inventiva in the fourth quarter worth about $6,039,000. Finally, Eventide Asset Management LLC bought a new position in shares of Inventiva in the fourth quarter worth about $1,155,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.